Equities research analysts expect Freeline Therapeutics Holdings plc (NASDAQ:FRLN) to report earnings per share (EPS) of ($1.00) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Freeline Therapeutics’ earnings. The lowest EPS estimate is ($1.12) and the highest is ($0.88). The company is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Freeline Therapeutics will report full year earnings of ($3.73) per share for the current financial year, with EPS estimates ranging from ($3.88) to ($3.39). For the next financial year, analysts anticipate that the company will report earnings of ($3.15) per share, with EPS estimates ranging from ($4.06) to ($1.89). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Freeline Therapeutics.
Freeline Therapeutics (NASDAQ:FRLN) last issued its quarterly earnings data on Monday, August 16th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.19).
Shares of FRLN stock traded up $0.05 during mid-day trading on Monday, hitting $3.35. 500 shares of the stock were exchanged, compared to its average volume of 113,436. The stock’s fifty day simple moving average is $3.66 and its two-hundred day simple moving average is $7.42. The stock has a market capitalization of $119.93 million, a price-to-earnings ratio of -0.49 and a beta of -0.95. Freeline Therapeutics has a 12-month low of $2.92 and a 12-month high of $18.88.
An institutional investor recently bought a new position in Freeline Therapeutics stock. Citadel Advisors LLC acquired a new stake in Freeline Therapeutics Holdings plc (NASDAQ:FRLN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,229 shares of the company’s stock, valued at approximately $108,000. Institutional investors own 31.54% of the company’s stock.
Freeline Therapeutics Company Profile
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B.
See Also: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.